MD-CERTIS-BIOLOGICALS
11.8.2021 15:19:08 CEST | Business Wire | Press release
To meet the rising demand for biological-based crop protection products, Certis Biologicals today announced new additions to its headquarters team. Tarang Srivastava begins immediately as Head of International Business, responsible for business strategy and financial objectives in international markets and working with distribution partners, external business partners and internal teams to expand biologicals globally. Srivastava’s focus will lay in providing solutions to growers in European markets. Srivastava formally worked on Bharat Certis Insecticide Limited for parent company Mitsui & Co. and brings extensive experience in establishing global positions to the new role.
Additionally, Certis Biologicals welcomes Moto Mitani to the International Business Team. Mitani will lead the Certis teams for Asia and Africa as well as supporting Certis Biologicals’ Specialty Chemical Sales division. Mitani joins from Mitsui AgriScience where he served as Business Manager responsible for international sales.
Amanda Eade joins the Global Marketing Team as Global Portfolio Manager for Bioinsecticides and Bioherbicides, assessing market capacity for Certis’ proven portfolio of bio-based insecticide and herbicide solutions, including Bt portfolio products, Firefighter© , Requiem Prime© and Homeplate© . Eade brings extensive experience from posts with Open Book Extracts as Operations Manager, BASF as portfolio manager and Dow Agrisciences as sales representative.
“Currently, Certis Biologicals distributes bio-based solutions in more than 50 countries worldwide and we see a growing need in areas where synthetic chemistries are growing scarce and regulations are high,” says Amy O’Shea, President and CEO. “We want to ensure that every grower, no matter where they are located, has access to our portfolio and we believe these additions to our staff will be key to achieving that goal.”
The additions of Srivastava, Mitani and Eade come in the wake of Certis Biologicals’ announcement that Rob Gibson joined as Global Product Manager and Ryutaro Matsuhashi, VP of International Business, had expanded his role within the biologicals leader to focus on growth in Latin America. In that capacity, Matsuhashi has seen success in expanding the company’s portfolio in Brazil.
“We are proud to be headquartered in the U.S., but Certis Biologicals is a true global distributor of biologicals,” says O’Shea. “We are investing in the talent and expertise needed to ensure that we can be the full-line provider of biologicals to all growers and distributors.”
Currently, Certis Biologicals innovates across six technology platforms, including bacteria-based technologies, fungi-based products, virus technologies, bacteriophage technologies, biochemicals and need-seed extracts. The company distributes nearly 40 integrated biological crop protection solutions to growers in more than 50 countries. Certis’ robust research and development pipeline is planning numerous new products and formulations coming to market over the next 3-5 years.
Growers and distributors who are interested in Certis Biologicals can visit www.CertisBio.com to learn more about the company’s portfolio of bio-solutions for organic and conventional farming.
About Certis Biologicals
Certis Biologicals is the leading manufacturer, innovator, developer and marketer of proven biological solutions for use in commercial agriculture and the garden and greenhouse markets.
With biological products sold through a global distribution network and in collaboration with various technology, regulatory and sourcing companies in more than 50 countries, Certis Biologicals meets the challenges faced by today’s growers around the globe to feed a growing population while sustaining the natural resources and environments necessary for a healthy planet.
To learn more about Certis Biologicals, their portfolio of proven solutions, or their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook , Twitter , LinkedIn and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom